Anti-amyloid Therapy of Alzheimer’s Disease: Current State and Prospects
- Authors: Kozin S.A.1, Barykin E.P.1, Mitkevich V.A.1, Makarov A.A.1
-
Affiliations:
- Engelhardt Institute of Molecular Biology
- Issue: Vol 83, No 9 (2018)
- Pages: 1057-1067
- Section: Review
- URL: https://journals.rcsi.science/0006-2979/article/view/151713
- DOI: https://doi.org/10.1134/S0006297918090079
- ID: 151713
Cite item
Abstract
Drug development for the treatment of Alzheimer’s disease (AD) has been for a long time focused on agents that were expected to support endogenous β-amyloid (Aβ) in a monomeric state and destroy soluble Aβ oligomers and insoluble Aβ aggregates. However, this strategy has failed over the last 20 years and was eventually abandoned. In this review, we propose a new approach to the anti-amyloid AD therapy based on the latest achievements in understanding molecular causes of cerebral amyloidosis in AD animal models.
About the authors
S. A. Kozin
Engelhardt Institute of Molecular Biology
Email: mitkevich@gmail.com
Russian Federation, Moscow, 119991
E. P. Barykin
Engelhardt Institute of Molecular Biology
Email: mitkevich@gmail.com
Russian Federation, Moscow, 119991
V. A. Mitkevich
Engelhardt Institute of Molecular Biology
Author for correspondence.
Email: mitkevich@gmail.com
Russian Federation, Moscow, 119991
A. A. Makarov
Engelhardt Institute of Molecular Biology
Email: mitkevich@gmail.com
Russian Federation, Moscow, 119991